Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
AesRx reports promising data for sickle cell disease drug
AesRx said data from a Phase I study of its sickle cell disease treatment Aes-103 showed the drug is safe and well-tolerated by patients. The data are set to be presented at a hematology meeting. Following the positive findings, AesRx has started a second trial at the NIH Clinical Center in Bethesda, Md., that will involve patients with sickle cell disease.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .